Alcoholism: A Modern Look at an Ancient Illness

Primary Care - Clinics in Office Practice

Volumn 38, Issue 1, 2011, Pages 9-21

  Carr, Gary D ^a,b,c  

^a Professionals Health Network Inc   (United States)

^b AMERICAN MEDICAL ASSOCIATION   (United States)

^c American Intervention Specialists   (United States)

Author keywords

Addiction treatment; Addictive illness; Alcohol abuse; Alcohol dependency; Alcoholism

Indexed keywords

ACAMPROSATE; ALCOHOL; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CITALOPRAM; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; FLUOXETINE; FOLIC ACID; HALOPERIDOL; LORAZEPAM; MAGNESIUM; NALTREXONE; OPIATE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; THIAMINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE TOXICITY; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLICS ANONYMOUS; ALCOHOLISM; ANXIETY; ARTHRALGIA; BEHAVIOR DISORDER; BRAIN DISEASE; CHILL; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DENIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISTRESS SYNDROME; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; EJACULATION DISORDER; FATIGUE; FLUSHING; FOLIC ACID DEFICIENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GROUP THERAPY; HUMAN; IMPOTENCE; IRRITABILITY; MAGNESIUM DEFICIENCY; MENTAL DISEASE; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOCIAL BEHAVIOR; SOCIOPATHY; SUBSTANCE ABUSE; SYMPTOM; THIAMINE DEFICIENCY; VOMITING; WITHDRAWAL SYNDROME;

ALCOHOLISM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PRIMARY HEALTH CARE; RECURRENCE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 79951987292     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.11.002     Document Type: Review

References (54)

1. Woodward J. The pharmacology of alcohol. Principles of addiction medicine 2003, 101-118. American Society of Addiction Medicine, Chevy Chase (MD). 3rd edition. A. Graham, K. Terry, M.F. Mayo-Smith (Eds.).
2. Berge K., Seppala M., Lanier W. The anesthesiology community's approach to opioid and anesthetic-abusing personnel. Anesthesiology 2008, 109:762-764.
3. National Institute on Drug Abuse NIDA InfoFacts: treatment approaches for drug addiction 2009, US Deprttment of Health and Human Services, Washington, DC, (Sept): all.
4. National Institute on Drug Abuse NIDA InfoFacts: treatment approaches for drug addiction 2008, US Department of Health and Human Services, Washington, DC, (June): all.
5. World Health Organization Global status report on alcohol 2004 Available at:, Accessed September 30, 2008. http://www.who.int/substance_abuse/publications/global_status_report_2004_overview.pdf.
6. Mokdad A., Marks J., Stroup D., et al. Actual causes of death in the United States, 2000. JAMA 2004, 291(10):1238-1245.
7. Centers for Disease Control and Prevention Alcohol and public health Available at:, Accessed September 30, 2008. http://www.cdc.gov/alcohol/.
8. Kaner E., Beyer F., Dickinson H., et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007, 2. CD004148.
9. Report of the Board of Trustees. JAMA 1956, 162:750.
10. Gastfriend D. Physician substance abuse and recovery: what does it mean for physicians-and everyone else?. JAMA 2005, 293:1513-1515.
11. Dupont R., McLellan T., Carr G., et al. How are addicted physicians treated? A national survey of physician health programs. J Subst Abuse Treat 2009, 37:1-7.
12. McLellan T., Skipper G., Campbell, et al. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ 2008, 337:a2038.
13. Mohn A., Yao W., Caron M. Genetic and genomic approaches to reward and addiction. Neuropharmacology 2004, 47:101-110.
14. Anton R. Naltrexone for the management of alcohol dependence. N Engl J Med 2008, 359(7):715-721.
15. Kobb G., Roberts A., Schulteis G., et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998, 22:3-9.
16. Fiellin D., Carrigton R., O'Connor P. New therapies for alcohol problems: application to primary care. Am J Med 2000, 108:227-237.
17. Grant B., Harford T., Dawson D., et al. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Res World 1994, 18(3):243-248.
18. Buchsbaum D., Buchanan R., Centor R., et al. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med 1991, 115(10):774-777.
19. Babor T., Higgins-Biddle J., Saunders J., et al. The Alcohol Use Disorders Identification Test: guidelines for use in primary care 2001, World Health Organization, Geneva (Switzerland), Available at:, Accessed September 30, 2008. http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.61.pdf, 2nd edition.
20. Willenbring M. National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician's guide and related professional support resources Available at:, Accessed September 30, 2008. http://www.niaaa.nih.gov/Publications/EducationTrainingMaterials/guide.htm.
21. Frances A. Substance related disorders. In: Diagnostic and statistical manual of mental disorders 2000, text revision (DSM-IV-TR), American Psychiatric Association, Arlington (VA), p. 197, 198, 212-22. 4th edition.
22. McGlynn E., Asch S., Adams J., et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348(26):2635-2645.
23. White R., Kitlowiski E. Physicians in recovery. Md Med J 1998, 37:183-189.
24. Tapper A., McKinney S., Nashmi R., et al. Nicotine activation of alpha 4 receptors: sufficient for reward, tolerance, and sensitization. Science 2004, 306:1029-1032.
25. Svhuckit M., Smith T. An 8-year follow-up of 450 sons of alcoholics and controls. Arch Gen Psychiatry 1996, 53:202-210.
26. Wang J., Hindrichs A., Stock H., et al. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 2004, 13:1903-1911.
27. Luo X., Kranzler H., Zuo L., et al. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 2005, 14:2421-2434.
28. Mayo-Smith M. Management of alcohol intoxication and withdrawal. Principles of addiction medicine 2003, 621-631. American Society of Addiction Medicine Inc, Chevy Chase (MD). 3rd edition. A. Graham, K. Terry, M.F. Mayo-Smith (Eds.).
29. Gordis E. Understanding alcoholism: insights from the research. Principles of addiction medicine 2003, 33-45. American Society of Addiction Medicine, Chevy Chase (MD). 3rd edition. A. Graham, K. Terry, M.F. Mayo-Smith (Eds.).
30. Krishnamoorthy S., Lip G., Lane D. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. Am J Med 2009, 22(9):851-856. e3.
31. Janzen L., Nanson J., Block G. Neuropsychological evaluation of preschoolers with fetal alcohol syndrome. Neurotoxicol Teratol 1995, 17(3):273-279.
32. Lau A., Dossow V., Sander M., et al. Alcohol use disorders and preoperative immune dysfunction. Anesth Analg 2009, 108:916-920.
33. Lowenfels A., Miller T. Alcohol and trauma. Ann Emerg Med 1984, 13:1056-1060.
34. Hall P., Hawkinberry H., Moyers-Scott P. Prescription drug abuse & addiction: past, present and future: the paradigm for an epidemic. W V Med J 2010, 106(4):24-30.
35. Dawson D., Grant B., Stinson F., et al. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 2005, 100(3):281-292.
36. Moss H., Chen C., Yi H. Subtypes of alcohol dependence in a nationally representative sample. Drug Alcohol Depend 2007, 91(2-3):149-158.
37. Tripodi S., Bender K., Litschge C., et al. Interventions for reducing adolescent alcohol abuse. Arch Pediatr Adolesc Med 2010, 164(1):85-91.
38. Brown S., McGue M., Maggs J., et al. A developmental perspective on alcohol and youths 16 to 20 years of age. Pediatrics 2008, 121:S290-S310.
39. Kirn T. Advances in understanding of alcoholism initiate evolution in treatment programs. JAMA 1986, 256:1405-1412.
40. Bryson E., Jeffrey S. Addiction and substance abuse in anesthesiology. Anesthesiology 2008, 109:905-917.
41. O'Connor P., Spickard A. Physician impairment by substance abuse. Med Clin North Am 1997, 81:1037-1052.
42. Glanter M., Casteneda R., Franco H. Group therapy and self-help groups. Clinical textbook of addictive disorders 1991, 431-451. Guilford Press, New York. R. Frances, S. Miller (Eds.).
43. Fuller R., Branchey L., Brightwell D., et al. Disulfiram treatment of alcoholism. A Veteran's Administration cooperative study. JAMA 1986, 256:1449-1455.
44. Kranzler H., Jaffe J. Pharmacologic interventions for alcoholism. Principles of addiction medicine 2003, 701-719. American Society of Addiction Medicine Inc, Chevy Chase (MD). 3rd edition. A. Graham, K. Terry, M.F. Mayo-Smith (Eds.).
45. Haley T. Disulfiram (tetraethylthioperoxydicarbonic diamide): a reappraisal of its toxicity and therapeutic application. Drug Metab Rev 1979, 9:319-355.
46. Johnson B., Rosenthal N., Capece J., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298(14):1641-1651.
47. Domino K.B., Hornbein T.F., Polissar N.L., et al. Risk factors for relapse in health care professionals with substance use disorders. JAMA 2005, 293:1453-1460.
48. Hankes L., Bissell L. Health professionals. Substance abuse: a comprehensive textbook 1992, 897-908. Williams & Wilkins, Baltimore (MD). J. Lowinson, P. Ruiz, R. Millman (Eds.).
49. Gentileoo L., Rivara F., Donovan D., et al. Alcohol interventions in a trauma center as a means of reducing the risk of injury recurrence. Ann Surg 1999, 230(4):473-483.
50. Monti P., Colby S., Barnett N., et al. Brief intervention for harm reduction with alcohol-positive older adolescents in a hospital emergency department. J Consult Clin Psychol 1999, 67(6):989-994.
51. Cassell S., Thamarangsi T. Reducing harm from alcohol: call to action. Lancet 2009, 373(9682):2173-2176.
52. Anderson P., Dan C., Fuhr D. Alcohol and Global Health 2. Effectiveness and cost-effectiveness of policies and programs to reduce the harm caused by alcohol. Lancet 2009, 373:2234-2246.
53. CALDATA data Evaluating recovery services: the California Drug and Alcohol Treatment Assessment, report to State of California Dept of Alcohol and Drug Programs Available at:, Accessed November 27, 2010. http://aspe.hhs.gov/hsp/caldrug/caldata.htm.
54. Finigan M. Societal outcomes and cost savings of drug and alcohol treatment in the state of Oregon February 20, 1996, Prepared for, Office of Alcohol and Drug Abuse Programs Oregon Department of Human Resources by Northwest Professionals Consortium.